Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

Détails

ID Serval
serval:BIB_4F0F8DC467FB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.
Périodique
Oncoimmunology
Auteur⸱e⸱s
Castenmiller S.M., Kanagasabesan N., Guislain A., Nicolet B.P., van Loenen M.M., Monkhorst K., Veenhof AAFA, Smit E.F., Hartemink K.J., Haanen JBAG, de Groot R., Wolkers M.C.
ISSN
2162-402X (Electronic)
ISSN-L
2162-4011
Statut éditorial
Publié
Date de publication
2024
Peer-reviewed
Oui
Volume
13
Numéro
1
Pages
2392898
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has proven highly effective for treating solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy for yet unknown reasons. Defining markers that correlate with high tumor-reactivity of the autologous TIL products is thus key for achieving better tailored immunotherapies. We questioned whether the composition of immune cell infiltrates correlated with the tumor-reactivity of expanded TIL products. Unbiased flow cytometry analysis of immune cell infiltrates of 26 early-stage and 20 late-stage NSCLC tumor lesions was used for correlations with the T cell differentiation and activation status, and with the expansion rate and anti-tumor response of generated TIL products. The composition of tumor immune infiltrates was highly variable between patients. Spearman's Rank Correlation revealed that high B cell infiltration negatively correlated with the tumor-reactivity of the patient's expanded TIL products, as defined by cytokine production upon exposure to autologous tumor digest. In-depth analysis revealed that tumor lesions with high B cell infiltrates contained tertiary lymphoid structure (TLS)-related immune infiltrates, including BCL6 <sup>+</sup> antibody-secreting B cells, IgD <sup>+</sup> BCL6 <sup>+</sup> B cells and CXCR5 <sup>+</sup> BLC6 <sup>+</sup> CD4 <sup>+</sup> T cells, and higher percentages of naïve CD8 <sup>+</sup> T cells. In conclusion, the composition of immune cell infiltrates in NSCLC tumors associates with the functionality of the expanded TIL product. Our findings may thus help improve patient selection for TIL therapy.
Mots-clé
Humans, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/pathology, Lung Neoplasms/immunology, Lung Neoplasms/pathology, Tertiary Lymphoid Structures/immunology, Tertiary Lymphoid Structures/pathology, Lymphocytes, Tumor-Infiltrating/immunology, Immunotherapy, Adoptive/methods, Female, Male, B-Lymphocytes/immunology, B-Lymphocytes/pathology, Middle Aged, Aged, Immune infiltrate, NSCLC, TIL therapy, TLS formation
Pubmed
Open Access
Oui
Création de la notice
30/08/2024 15:48
Dernière modification de la notice
03/10/2024 6:06
Données d'usage